CONTENIDO JUL-DIC. 07 MARZO.Pmd
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
If Needed You Can Use Two Lines
“IS AN OLD FOE MAKING A COMEBACK?” •Eyob Tadesse MD1; Samie Meskele MD1; Ankoor Biswas MD1 •Aurora Health Care, Milwaukee WI. NTRODUCTION abdomen gradually spread to her extremities, DISCUSSION I scalp, palms and soles. In association she had After being on the verge of elimination in shortness of breath, vague abdominal pain Generally, syphilis presents in HIV infected 2000 in the United States, syphilis cases have and loss of appetite, history of multiple sexual patients similar to general population yet with rebounded. Rates of primary and secondary partner, unprotected sex and prostitution. She some differences. Diagnosis is based on syphilis continued to increase overall during was recently diagnosed with HIV but not serologic test and microbiology. For serology, 2005–2013. Increases have occurred primarily started on treatment. both non treponemal antibody test, and among men, and particularly among men has specific treponemal antibody test should be used. Secondary syphilis in patients with HIV sex with men (MSM)(1). According to CDC During her admission her vital signs were has varied skin presentation, which can mimic report the incidence of primary and stable, she had pale conjunctivae, skin cutaneous lymphoma, mycobacterial secondary syphilis during 2015–2016, examination had demonstrated widespread macular and maculopapular skin lesions infection, bacillary angiomatosis, fungal increased 17.6% to 8.7 cases per 100,000 infections or Kaposi’s sarcoma. In our patient, population, the highest rate reported since involving the whole body including palms and soles. She also had thin, fragile scalp hair and she was having diffuse maculopapular rash, 1993(2). HIV and syphilis affect similar patient scalp hair loss without genital ulceration; involving palms and soles, significant hair loss, groups and co-infection is common(3). -
Genetic Diversity of Bartonella Species in Small Mammals in the Qaidam
www.nature.com/scientificreports OPEN Genetic diversity of Bartonella species in small mammals in the Qaidam Basin, western China Huaxiang Rao1, Shoujiang Li3, Liang Lu4, Rong Wang3, Xiuping Song4, Kai Sun5, Yan Shi3, Dongmei Li4* & Juan Yu2* Investigation of the prevalence and diversity of Bartonella infections in small mammals in the Qaidam Basin, western China, could provide a scientifc basis for the control and prevention of Bartonella infections in humans. Accordingly, in this study, small mammals were captured using snap traps in Wulan County and Ge’ermu City, Qaidam Basin, China. Spleen and brain tissues were collected and cultured to isolate Bartonella strains. The suspected positive colonies were detected with polymerase chain reaction amplifcation and sequencing of gltA, ftsZ, RNA polymerase beta subunit (rpoB) and ribC genes. Among 101 small mammals, 39 were positive for Bartonella, with the infection rate of 38.61%. The infection rate in diferent tissues (spleens and brains) (χ2 = 0.112, P = 0.738) and gender (χ2 = 1.927, P = 0.165) of small mammals did not have statistical diference, but that in diferent habitats had statistical diference (χ2 = 10.361, P = 0.016). Through genetic evolution analysis, 40 Bartonella strains were identifed (two diferent Bartonella species were detected in one small mammal), including B. grahamii (30), B. jaculi (3), B. krasnovii (3) and Candidatus B. gerbillinarum (4), which showed rodent-specifc characteristics. B. grahamii was the dominant epidemic strain (accounted for 75.0%). Furthermore, phylogenetic analysis showed that B. grahamii in the Qaidam Basin, might be close to the strains isolated from Japan and China. -
HIV and the SKIN • Sudden Acute Exacerbations • Treatment Failure DR
2018/08/13 KEY FEATURES • Atypical presentation of common disorders • Severe or exaggerated presentations HIV AND THE SKIN • Sudden acute exacerbations • Treatment failure DR. FREDAH MALEKA DERMATOLOGY UNIVERSITY OF PRETORIA:KALAFONG VIRAL INFECTIONS EXANTHEM OF PRIMARY HIV INFECTION • Exanthem of primary HIV infection • Acute retroviral syndrome • Herpes simplex virus (HSV) • Morbilliform rash (exanthem) : 2-4 weeks after HIV exposure • Varicella Zoster virus (VZV) • Typically generalised • Molluscum contagiosum (Poxvirus) • Pronounced on face and trunk, sparing distal extremities • Human papillomavirus (HPV) • Associated : fever, lymphadenopathy, pharyngitis • Epstein Barr virus (EBV) • DDX: drug reaction • Cytomegalovirus (CMV) • other viral infections – EBV, Enteroviruses, Hepatitis B virus 1 2018/08/13 HERPES SIMPLEX VIRUS(HSV) • Vesicular eruption due to HSV 1&2 • Primary lesion: painful, grouped vesicles on an erythematous base • HIV: attacks are more frequent and severe • : chronic, non-healing, deep ulcers, with scarring and tissue destruction • CLUE: severe pain and recurrences • DDX: syphilis, chancroid, lymphogranuloma venereum • Tzanck smear, Histology, Viral culture HSV • Treatment: Acyclovir 400mg tds 7-10 days • Alternatives: Valacyclovir and Famciclovir • In setting of treatment failure, viral isolates tested for resistance against acyclovir • Alternative drugs: Foscarnet, Cidofovir • Chronic suppressive therapy ( >8 attacks per year) 2 2018/08/13 VARICELLA • Chickenpox • Presents with erythematous papules and umbilicated -
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
Rheumatic Manifestations of Bartonella Infection in 2 Children MOHAMMAD J
Case Report Rheumatic Manifestations of Bartonella Infection in 2 Children MOHAMMAD J. AL-MATAR, ROSS E. PETTY, DAVID A. CABRAL, LORI B. TUCKER, BANAFSHI PEYVANDI, JULIE PRENDIVILLE, JACK FORBES, ROBYN CAIRNS, and RALPH ROTHSTEIN ABSTRACT. We describe 2 patients with very unusual rheumatological presentations presumably caused by Bartonella infection: one had myositis of proximal thigh muscles bilaterally, and the other had arthritis and skin nodules. Both patients had very high levels of antibody to Bartonella that decreased in asso- ciation with clinical improvement. Bartonella infection should be considered in the differential diag- nosis of unusual myositis or arthritis in children. (J Rheumatol 2002;29:184–6) Key Indexing Terms: MYOSITIS ARTHRITIS BARTONELLA Infection with Bartonella species has a wide range of mani- was slightly increased at 9.86 IU/l (normal 4.51–9.16), and IgA was 2.1 IU/l festations in children including cat scratch disease (regional (normal 0.2–1.0). C3 was 0.11 g/l (normal 0.77–1.43) and C4 was 0.28 (nor- mal 0.07–0.40). Antinuclear antibodies were present at a titer of 1:40, the anti- granulomatous lymphadenitis), bacillary angiomatosis, streptolysin O titer was 35 (normal < 200), and the anti-DNAase B titer was encephalitis, Parinaud’s oculoglandular syndrome, Trench 1:85 (normal). Urinalysis showed 50–100 erythrocytes and 5–10 leukocytes fever (Vincent’s angina), osteomyelitis, granulomatous per high power field. Routine cultures of urine, blood, and throat were nega- hepatitis, splenitis, pneumonitis, endocarditis, and fever of tive. Liver enzymes, electrolytes, HIV serology, cerebrospinal fluid analysis, unknown origin1-3. -
An Important One Health Opportunity
veterinary sciences Review Ehrlichioses: An Important One Health Opportunity Tais B. Saito * and David H. Walker Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-1409-772-4813 Academic Editor: Ulrike Munderloh Received: 15 July 2016; Accepted: 25 August 2016; Published: 31 August 2016 Abstract: Ehrlichioses are caused by obligately intracellular bacteria that are maintained subclinically in a persistently infected vertebrate host and a tick vector. The most severe life-threatening illnesses, such as human monocytotropic ehrlichiosis and heartwater, occur in incidental hosts. Ehrlichia have a developmental cycle involving an infectious, nonreplicating, dense core cell and a noninfectious, replicating reticulate cell. Ehrlichiae secrete proteins that bind to host cytoplasmic proteins and nuclear chromatin, manipulating the host cell environment to their advantage. Severe disease in immunocompetent hosts is mediated in large part by immunologic and inflammatory mechanisms, including overproduction of tumor necrosis factor α (TNF-α), which is produced by CD8 T lymphocytes, and interleukin-10 (IL-10). Immune components that contribute to control of ehrlichial infection include CD4 and CD8 T cells, natural killer (NK) cells, interferon-γ (IFN-γ), IL-12, and antibodies. Some immune components, such as TNF-α, perforin, and CD8 T cells, play both pathogenic and protective roles. In contrast with the immunocompetent host, which may die with few detectable organisms owing to the overly strong immune response, immunodeficient hosts die with overwhelming infection and large quantities of organisms in the tissues. Vaccine development is challenging because of antigenic diversity of E. -
Endocarditis Due to Bartonella Quintana, the Etiological Agent of Trench Fever
PRACTICE | CASES CPD VULNERABLE POPULATIONS Endocarditis due to Bartonella quintana, the etiological agent of trench fever Carl Boodman MD, Terence Wuerz MD MSc (Epi), Philippe Lagacé-Wiens MD n Cite as: CMAJ 2020 December 7;192:E1723-6. doi: 10.1503/cmaj.201170 CMAJ Podcasts: author interview at www.cmaj.ca/lookup/doi/10.1503/cmaj.201170/tab-related-content 48-year-old man presented to the emergency depart- ment with a 2-day history of pleuritic chest pain and KEY POINTS shortness of breath. His medical history included HIV • Bartonella quintana, the causal agent of trench fever, is infection,A diagnosed 14 years earlier in the context of intraven- transmitted by body lice (Pediculus humanus var. corporis). ous drug use. Three months previously, he had an undetectable • Although B. quintana is notorious for causing disease in the First viral load and a CD4 count of 94 cells/mm3 (normal range: 500– World War, outbreaks of trench fever have recently occurred in 1400 cells/mm3) or 0.09 (normal range 0.50–1.40) × 109/L. The urban populations experiencing homelessness. patient adhered to his prescribed antiretroviral regimen (darunavir, • B. quintana causes culture-negative endocarditis and may be ritonavir and abacavir-lamivudine) and prophylaxis against oppor- fatal without antimicrobial and surgical treatment, despite mild tunistic infections (valacyclovir, trimethoprim-sulfamethoxazole symptomatology during chronic bacteremia. Consultation with infectious disease specialists is encouraged. and fluconazole). In addition, the patient had a congenital soli- Because B. quintana evades identification in routine blood tary kidney with normal baseline renal function, alcohol expos- • cultures, diagnosis of B. -
The Approved List of Biological Agents Advisory Committee on Dangerous Pathogens Health and Safety Executive
The Approved List of biological agents Advisory Committee on Dangerous Pathogens Health and Safety Executive © Crown copyright 2021 First published 2000 Second edition 2004 Third edition 2013 Fourth edition 2021 You may reuse this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view the licence visit www.nationalarchives.gov.uk/doc/ open-government-licence/, write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email [email protected]. Some images and illustrations may not be owned by the Crown so cannot be reproduced without permission of the copyright owner. Enquiries should be sent to [email protected]. The Control of Substances Hazardous to Health Regulations 2002 refer to an ‘approved classification of a biological agent’, which means the classification of that agent approved by the Health and Safety Executive (HSE). This list is approved by HSE for that purpose. This edition of the Approved List has effect from 12 July 2021. On that date the previous edition of the list approved by the Health and Safety Executive on the 1 July 2013 will cease to have effect. This list will be reviewed periodically, the next review is due in February 2022. The Advisory Committee on Dangerous Pathogens (ACDP) prepares the Approved List included in this publication. ACDP advises HSE, and Ministers for the Department of Health and Social Care and the Department for the Environment, Food & Rural Affairs and their counterparts under devolution in Scotland, Wales & Northern Ireland, as required, on all aspects of hazards and risks to workers and others from exposure to pathogens. -
Bartonella: Feline Diseases and Emerging Zoonosis
BARTONELLA: FELINE DISEASES AND EMERGING ZOONOSIS WILLIAM D. HARDY, JR., V.M.D. Director National Veterinary Laboratory, Inc. P.O Box 239 Franklin Lakes, New Jersey 07417 201-891-2992 www.natvetlab.com or .net Gingivitis Proliferative Gingivitis Conjunctivitis/Blepharitis Uveitis & Conjunctivitis URI Oral Ulcers Stomatitis Lymphadenopathy TABLE OF CONTENTS Page SUMMARY……………………………………………………………………………………... i INTRODUCTION……………………………………………………………………………… 1 MICROBIOLOGY……………………………………………………………………………... 1 METHODS OF DETECTION OF BARTONELLA INFECTION.………………………….. 1 Isolation from Blood…………………………………………………………………….. 2 Serologic Tests…………………………………………………………………………… 2 SEROLOGY……………………………………………………………………………………… 3 CATS: PREVALENCE OF BARTONELLA INFECTIONS…………………………………… 4 Geographic Risk factors for Infection……………………………………………………. 5 Risk Factors for Infection………………………………………………………………… 5 FELINE BARTONELLA DISEASES………………………………………………………….… 6 Bartonella Pathogenesis………………………………………………………………… 7 Therapy of Feline Bartonella Diseases…………………………………………………… 14 Clinical Therapy Results…………………………………………………………………. 15 DOGS: PREVALENCE OF BARTONELLA INFECTIONS…………………………………. 17 CANINE BARTONELLA DISEASES…………………………………………………………... 17 HUMAN BARTONELLA DISEASES…………………………………………………………… 18 Zoonotic Case Study……………………………………………………………………... 21 FELINE BLOOD DONORS……………………………………………………………………. 21 REFERENCES………………………………………………………………………………….. 22 This work was initiated while Dr. Hardy was: Professor of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York and Director, -
Circulatory and Lymphatic System Infections 1105
Chapter 25 | Circulatory and Lymphatic System Infections 1105 Chapter 25 Circulatory and Lymphatic System Infections Figure 25.1 Yellow fever is a viral hemorrhagic disease that can cause liver damage, resulting in jaundice (left) as well as serious and sometimes fatal complications. The virus that causes yellow fever is transmitted through the bite of a biological vector, the Aedes aegypti mosquito (right). (credit left: modification of work by Centers for Disease Control and Prevention; credit right: modification of work by James Gathany, Centers for Disease Control and Prevention) Chapter Outline 25.1 Anatomy of the Circulatory and Lymphatic Systems 25.2 Bacterial Infections of the Circulatory and Lymphatic Systems 25.3 Viral Infections of the Circulatory and Lymphatic Systems 25.4 Parasitic Infections of the Circulatory and Lymphatic Systems Introduction Yellow fever was once common in the southeastern US, with annual outbreaks of more than 25,000 infections in New Orleans in the mid-1800s.[1] In the early 20th century, efforts to eradicate the virus that causes yellow fever were successful thanks to vaccination programs and effective control (mainly through the insecticide dichlorodiphenyltrichloroethane [DDT]) of Aedes aegypti, the mosquito that serves as a vector. Today, the virus has been largely eradicated in North America. Elsewhere, efforts to contain yellow fever have been less successful. Despite mass vaccination campaigns in some regions, the risk for yellow fever epidemics is rising in dense urban cities in Africa and South America.[2] In an increasingly globalized society, yellow fever could easily make a comeback in North America, where A. aegypti is still present. -
Bartonella Species Isolated from Rodents, Greece
LETTERS Bartonella Species Germany). Polymerase chain reaction (AY435104–AY435113, isolated from (PCR) was performed by using two A. flavicollis) and representing four Isolated from oligonucleotides specific for the cit- novel genotypes, was 98% similar to Rodents, Greece rate synthase (gltA) gene of B. hense- B. taylorii (AF191502, isolated from lae Houston 1, primers BhCS 781.p A. sylvaticus) gltA gene. The second To the Editor: Domestic cats and and BhCS 1137.n. Negative and posi- group, consisting of seven isolates that human body lice have been identified tive controls (double-distilled H2O shared the same genotype (AY435114- as the vectors of Bartonella henselae and DNA from cultures of B. hense- AY435120 isolated from A. flavicol- and B. quintana, respectively, the pri- lae) were used in each PCR run. lis), was 99% similar to B. birtlesii mary sources of Bartonella-associat- Products of the correct size were puri- (AF204272 isolated from Apodemus ed human diseases (1). Bartonella fied (QIAquick PCR Purification kit, spp.). The third group consisted of two species are zoonotic agents that have Qiagen GmbH) and sequenced with isolates that shared the same genotype been isolated from a wide range of the same primers, BhCS 781.p and (AY435121 isolated from D. nitedula, mammals in the United States (2) and BhCS1137.n., in both directions, with and AY435122 isolated from A. flavi- Europe (3) and have been associated the Cy5/Cy5.5 Dye Primer Cycle collis); this group was 97% similar to with human diseases (4–5). Sequencing kit on a Long-Read B. grahamii strain V2 (Z70016 isolat- This study investigated the poten- Tower sequencer (Visible Genetics ed from Neomys fodiens). -
INFECTIOUS DISEASES of HAITI Free
INFECTIOUS DISEASES OF HAITI Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Infectious Diseases of Haiti - 2010 edition Copyright © 2010 by GIDEON Informatics, Inc. All rights reserved. Published by GIDEON Informatics, Inc, Los Angeles, California, USA. www.gideononline.com Cover design by GIDEON Informatics, Inc No part of this book may be reproduced or transmitted in any form or by any means without written permission from the publisher. Contact GIDEON Informatics at [email protected]. ISBN-13: 978-1-61755-090-4 ISBN-10: 1-61755-090-6 Visit http://www.gideononline.com/ebooks/ for the up to date list of GIDEON ebooks. DISCLAIMER: Publisher assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this book. Therapeutic options listed are limited to published studies and reviews. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the data for the book are largely derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and countries. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. © 2010 GIDEON Informatics, Inc. www.gideononline.com All Rights Reserved. Page 2 of 314 Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Introduction: The GIDEON e-book series Infectious Diseases of Haiti is one in a series of GIDEON ebooks which summarize the status of individual infectious diseases, in every country of the world.